Author of

• 11890

  +

  P2.19 - Poster Session 2 - Imaging (ID 180)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Imaging, Staging & Screening
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11891

    +

    P2.19-001 - The Imaging Characteristics of F-18 FDG PET-CT on Epidermal Growth Factor Receptor Mutations in Non-small cell Lung Cancer (ID 291)

    09:30 - 09:30  |  Author(s): G. Calibasi
    • Abstract

    Background
    Aim: We aimed to compare F-18 FDG PET-CT imaging characterictics in non-small cell lung cancer (NSCLC) with and without epidermal growth factor (EGFR) reseptor mutation.

    Methods
    Methods: A total of 47 NSCLC patients (38 male, 9 female, mean age : 47±10.45 )were included in this retrospective study. All patients underwent EGFR mutation resting and pretreatment F-18 FDG PET-CT scan. The maksimum standardized uptake (SUVmax) of the primary tumor and metastases was calculated for all lesions in all patients. We compared the SUVmax values for primary tumor and metastatic lesions in patients with and without EGFR receptor mutation.

    Results
    Results: In our study group, there were 17 adeno, 10 squamous, 2 large cell, 1 mixt-type and 17 non-small cell cancer patients. Seven patients had EGFR-mutant and 40 patients had EGFR wild-type tumors. There was a trend for higher SUVmax in primary tumors among patients with EGFR-mutant (mean SUVmax: 14.20±10.40) versus patients with wild-type EGFR (mean SUVmax:11.53±6.46). In patients with wild-type EGFR, the mean SUVmax was 7.05±3.39, 7.83±4.66, 6.10±4.44, 12.83±4.89 for hilar(17 pts), unilateral mediastinal (23 pts), contralateral mediastinal (13pts) and supraclavicular (3 pts) lymph node metastates (LNM), respectively. In 5 patients with EGFR-mutant , SUVmax was 6.48±3.39 for unilateral mediastinal LNM. There was no hilar, contralateral and supraclavicular LNM which can be demonstrated by F-18 FDG PET-CT in EGFR-mutant patients. The mean SUVmax was 7.97±6.67, 8.98±4.31 and 5.85±3.39 for lung (6 pts), bone (9 pts) and adrenal (6 pts) metastases in wild- type EGFR patient group. In EGFR-mutant group , one patient had lung, bone and adrenal metastases in which SUVmax was 4.20, 11.20 and 22.20, respectively.

    Conclusion
    Conclusion: Higher FDG uptake was found in primary tumors among EGFR-mutant patients than wild-type EGFR patients. In this study group, the incidence of hilar, contralateral mediastinal and supraclavicular LNM were higher in wild-type EGFR group than that in EGFR-mutant group. Bone and adrenal metastases in a patient with EGFR-mutant showed markedly increased FDG uptake. Further analyses with large number of patients are needed to describe a predictive role of FDG uptake on EGFR mutations in NSCLC patients.